Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic ... Now given the brand name Saphnelo, the antibody is the first type I interferon receptor antagonist to be ...

A newer lupus drug can protect patients from long-term organ damage Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...

Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...

Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...